$DELL

Here are Tuesday's biggest analyst calls: Nvidia, SpaceX, Netflix, Marvell, AMD, Coinbase, Moderna & more

Analysts made several calls on Tuesday. JPMorgan raised Dell's price target to $565, citing expected revenue growth. Wolfe upgraded Moderna to peer perform, noting its focus on therapeutics. UBS upgraded Fluence to neutral, seeing an earnings trough. Morgan Stanley upgraded Dynatrace to overweight, forecasting growth. Goldman initiated Jersey Mike's as neutral, citing full valuation. Wolfe upgraded Netflix to outperform, raising its price target to $95. Bank of America reiterated Nvidia, Micron,

Original reporting
Published Aug 25, 2026, 1:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 25, 2026, 2:32 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Here are Tuesday's biggest analyst calls: Nvidia, SpaceX, Netflix, Marvell, AMD, Coinbase, Moderna & more — source image
Decision brief

The 30-second read

$DELLBullishLow
01

Why it matters

The collective rating changes may generate modest buying pressure but lack underlying new fundamentals.

02

Market read

The article is a post-earnings analyst reaction roundup with limited actionable insight.

03

What to watch

Absence of new earnings or macro catalysts reduces the durability of these rating changes.

Relevance 5/10Novelty 2/10Timing: today

Background

Analyst houses released a series of upgrades, initiations, and price target adjustments across a range of US-listed companies.

Company-level read

Ticker impact

$DELLBullishMedium confidence
Context

JPMorgan raised price target to $565 ahead of earnings.

Expected impact

Modest upside if earnings beat expectations.

Evidence & confidence

Analyst upgrade signals confidence but no new earnings data.

$MRNABullishMedium confidence
Context

Wolfe upgrades Moderna to peer perform.

Expected impact

Potential modest rally.

Evidence & confidence

Upgrade without new data.

$CURBBullishMedium confidence
Context

Jefferies initiates Curbline Properties as buy.

Expected impact

Small upside potential.

Evidence & confidence

First coverage may draw attention.

$FLNCNeutralLow confidence
Context

UBS upgrades Fluence to neutral from sell.

Expected impact

Limited price movement.

Evidence & confidence

Upgrade reflects outlook, no new fundamentals.

$SHWBullishMedium confidence
Context

DA Davidson initiates Sherwin-Williams as buy with $400 PT.

Expected impact

Potential upside if earnings sustain.

Evidence & confidence

Analyst confidence but no fresh data.

$DTBullishMedium confidence
Context

Morgan Stanley upgrades Dynatrace to overweight.

Expected impact

Modest upside.

Evidence & confidence

Analyst view without new earnings.

$JMKENeutralLow confidence
Context

Goldman Sachs initiates Jersey Mike's as neutral.

Expected impact

Sideways to slight downside.

Evidence & confidence

Initiation without catalyst.

$FIVEBearishLow confidence
Context

Loop downgrades Five Below to hold from buy.

Expected impact

Potential modest decline.

Evidence & confidence

Downgrade alone.

Market effects

Broad analyst upgrades may lift sector sentiment in tech and consumer discretionary.

US market sentiment modestly positive due to multiple buy/overweight calls.

Limited global impact; primarily US equity focus.

Counterpoint

Many upgrades may be premature without fresh earnings data; price targets could be overstated.

Key entities

  • JPMorgan

    Raised Dell target

  • Wolfe

    Upgraded Moderna, Bread Financial, Netflix

Related articles

$MRVLMedAI 8/10

Is Marvell stock a buy after its post-earnings sell-off?

Marvell (MRVL) fell 8.8% after-hours despite beating Q2 estimates and raising FY2027 guidance to $12B. Analysts cite high valuation (80x P/E) and margin concerns. Bull case highlights 4x revenue growth by FY2029; bear case warns of customer concentration and cyclical risks. Technical indicators suggest oversold conditions.

$BNTXHighAI 8/10

BioNTech drops 10% on mRNA trial failure, highlighting Moderna contrast

BioNTech SE (BNTX) shares fell 10% after terminating a Phase 2 mRNA cancer vaccine trial for colorectal cancer due to futility. The setback contrasts with Moderna's recent success in melanoma, highlighting different outcomes in cancer types. BioNTech has €16.6B in cash and securities, and other trials remain ongoing. Investors await further data at ESMO Congress in October 2026.

$NVDAHighAI 9/10

Nvidia's Margin Pressure Is Micron's Revenue Boost

Nvidia (NVDA) reported Q2 2027 revenue up 106% YoY, with data center sales rising 117%. However, gross margins are expected to drop from 75% to 71-72% in Q4 due to rising memory costs. Nvidia's CFO attributed this to supply constraints from memory suppliers Micron (MU), Samsung, and SK Hynix, which are benefiting from increased demand. Nvidia expects margins to recover in fiscal 2028 as price increases take effect.

$NVDAMed

Nvidia May Have Just Eliminated Its Biggest Risk

Nvidia (NVDA) reported record revenue of $96B and profit of $59B, up 106% and 126% respectively. Despite competition from AMD and Amazon (AMZN), Nvidia expanded its partnership with AWS, securing a deal for 2M GPUs and potentially millions of CPUs. Amazon's continued investment suggests Nvidia's leadership remains strong.

$NVDAHighAI 9/10

Will Nvidia or Apple Have The Bigger Market Cap By The End of Q3?

NVIDIA (NVDA) leads Apple (AAPL) in market cap ($5.52T vs. $4.59T) after reporting 106% revenue growth, driven by AI infrastructure demand. Apple's Q3 revenue grew 16.36%, with strong iPhone 17 sales. NVIDIA projects $1.3T AI spending by 2027, while Apple focuses on ecosystem growth. Investors weigh AI-driven growth vs. defensive trade.